RRPV | Rapid Response Partnership Vehicle

The Rapid Response Partnership Vehicle (RRPV) supports the Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure (MCM) product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats. It is an agile network of technologists, innovators, traditional contractors, large and small business, academia, and nonprofit research institutions that can respond rapidly and effectively to future pandemic or high consequence biological threats. The consortium brings together members focused on Medical Technology (MedTech), Vaccines (Vx), and Therapeutics (Tx) to accelerate partnering, improve responsiveness, and meet expanding demand to develop future MCM products. These products will range from early-stage development through advanced development, procurement, sustainment, and commercialization, including manufacturing infrastructure development. The consortium will advance health security, enhance preparedness, and enable a rapid response to the next pandemic or public health emergency.